TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37889487
Drug: Daily Calorie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Calorie Restriction (CR)
Study: 39132335
Drug: One-month dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-month dual antiplatelet therapy (DAPT)
Study: 33638263
Drug: Treatment-naïve patients
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-naïve patients
Study: 34152395
Drug: Zanubrutinib 320
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanubrutinib 320 mg once daily
Study: 32171470
Drug: Androgen-deprivation therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen-deprivation therapies (ADTs)
Study: 33435412
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group not specified; details on control treatment not available.
Study: 33251753
Drug: Telephone-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based cognitive behavioural therapy (Tele-CBT)
Study: 36513815
Drug: Pressurized intraperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
Study: 34094549
Drug: Low-dose interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose interleukin-2 (IL-2) therapy
Study: 32428369
Drug: Susceptibility-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Susceptibility-guided therapy
Study: 35212470
Drug: Antiretroviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral treatment (ART)
Study: 32271899
Drug: Tisagenlecleucel infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tisagenlecleucel infusion
Study: 36209432
Drug: Decongestive lymphatic
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decongestive lymphatic therapy (DLT)
Study: 32581513
Drug: Agalsidase alfa
Normalized name: Agalsidase alfa
DrugBank: Agalsidase alfa (DB15874)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Agalsidase alfa enzyme replacement therapy (ERT)
Study: 37646208
Drug: Angiotensin-Converting Enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-Converting Enzyme Inhibitors (ACEIs)
Study: 38670599
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (specific treatment not mentioned)
Study: 34006291
Drug: Matched therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched therapy
Study: 35238467
Drug: Unmatched therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unmatched therapy
Study: 37924481
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (IVT-AFL) treatment
Study: 37326854
Drug: Belimumab 10
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab 10 mg/kg IV
Study: 32000408
Drug: Instrumental activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instrumental activities of daily living scale (IADL)
Study: 32000590
Drug: Anticoagulation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation treatment for atrial fibrillation after intracerebral hemorrhage
Study: 32000819
Drug: Multisession radiosurgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisession radiosurgery delivering 25 Gy in 5 daily fractions
Study: 32003099
Drug: Second-line insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second-line insulin secretagogues (IS) or insulin
Study: 32003099
Drug: No IS
Normalized name: Alpha amino isobutyric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No IS and insulin
Study: 32003749
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted cognitive behavioral internet-delivered treatment
Study: 32004245
Drug: Multipoint pacing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multipoint pacing (MPP) activated ON at implant for patients with RV-to-LV delay less than 80 ms
Study: 32005112
Drug: Standardized questionnaires
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized questionnaires administered at three time points (t1, t2, t3)
Study: 32005333
Drug: Smartphone-delivered individual
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone-delivered individual cognitive-behavioral therapy (CBT) for BDD
Study: 32011909
Drug: SPT-Intense (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPT-Intense (3 hourly sessions per day/3 days per week)
Study: 32012106
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments for UTUC (specific treatments not detailed)
Study: 32012114
Drug: Nurse-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-delivered cognitive behavioral therapy (CBT-AD) for adherence and depression; 8 sessions.
Study: 32012114
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment as usual (control group).
Study: 32012214
Drug: Loncastuximab tesirine
Normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loncastuximab tesirine at 15 to 150 μg/kg IV once every 3 weeks (Q3W) or 50 μg/kg IV weekly.
Study: 32015419
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of tolvaptan and pioglitazone
Study: 32016127
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) for 3 years
Study: 32016427
Drug: AMH in
Normalized name: Sodium Fluoride 0.007 mg in 35 mL ORAL SPRAY [AMHEALER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMH in early postmenarchal girls (5.2 ± 0.3 ng/mL)
Study: 32016643
Drug: 24-h urinary
Normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-h urinary excretion measurement
Study: 32016643
Drug: Correlation analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation analysis between self-reported intake and urinary excretion
Study: 32017341
Drug: Ulimorelin 600-1200
Normalized name: Ulimorelin
DrugBank: Ulimorelin (DB12128)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulimorelin 600-1200 µg/kg
Study: 32017341
Drug: Ulimorelin 150-600
Normalized name: Ulimorelin
DrugBank: Ulimorelin (DB12128)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulimorelin 150-600 µg/kg
Study: 32017433
Drug: Individualized appropriate
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized appropriate medical therapy (AMT)
Study: 32019278
Drug: Anthracycline-Taxane-Based Neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline-Taxane-Based Neoadjuvant Chemotherapy
Study: 32019278
Drug: Carboplatin-containing treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin-containing treatment
Study: 37789300
Drug: 38% Silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: 38% Silver Diamine Fluoride (SDF) solution
Study: 32020437
Drug: RO6839921 (inactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO6839921 (inactive pegylated prodrug of idasanutlin) administered at doses of 120-300 mg, with maximum tolerated dose (MTD) identified as 200 mg.
Study: 32020437
Drug: RO6839921 (inactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO6839921 (inactive pegylated prodrug of idasanutlin) administered at doses of 120-300 mg.
Study: 32021066
Drug: Baerveldt-350 glaucoma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baerveldt-350 glaucoma implant (BGI)
Study: 32021066
Drug: Ahmed glaucoma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ahmed glaucoma implant (AGV-S2 and FP7 models)
Study: 32021387
Drug: Low-dose manual
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose manual acupuncture (MAL)
Study: 32021387
Drug: High-dose manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose manual acupuncture (MAH)
Study: 32021913
Drug: Nitroglycerin (Transiderm-Nitro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (Transiderm-Nitro 5 patch) during radiotherapy
Study: 32022437
Drug: Videolaryngoscopy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videolaryngoscopy and combination techniques for intubation
Study: 32022692
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy program (Breathe)
Study: 32024786
Drug: Multicomponent menstrual
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent menstrual health management (MHM) intervention including teacher training, menstrual kit use, pain management, drama skit, provision of analgesics, and improvements to school facilities.
Study: 32025741
Drug: IncobotulinumtoxinA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IncobotulinumtoxinA treatment (shoulder injections)
Study: 32025741
Drug: No shoulder
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: No shoulder treatment (control group)
Study: 32026243
Drug: Pirfenidone, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirfenidone, administered in three divided doses daily, median dose 2400 mg/day, exposure duration median 3.0 years.
Study: 32026347
Drug: Pirfenidone, mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirfenidone, mean (SD) daily dose 2058.7 (399.2) mg, mean (SD) exposure 22.8 (9.6) weeks
Study: 32026407
Drug: Vismodegib 150
Normalized name: vismodegib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vismodegib 150 mg plus pirfenidone 2403 mg/day once daily
Study: 32026411
Drug: Ambroxol 20
Normalized name: ambroxol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol 20 mg hard-boiled lozenges
Study: 32026411
Drug: Placebo hard-boiled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo hard-boiled lozenges
Study: 32026814
Drug: Therapy interventions
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy interventions
Study: 32027846
Drug: Osimertinib 80
Normalized name: osimertinib 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib 80 mg plus savolitinib 600 mg daily (part B)
Study: 32027846
Drug: Osimertinib 80
Normalized name: osimertinib 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib 80 mg plus savolitinib 300 mg daily (part D)
Study: 32028209
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg every 2 weeks until progression or unacceptable toxicity
Study: 32028985
Drug: 3 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 weeks of targeted postsurgical systemic antibiotic therapy for implant-free SIs
Study: 32028985
Drug: 6 weeks
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 weeks of targeted postsurgical systemic antibiotic therapy for implant-related SIs
Study: 32028985
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events of antibiotic therapy
Study: 32028991
Drug: HepaStem (liver-derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: HepaStem (liver-derived mesenchymal stem cells) with anticoagulants (heparin and bivalirudin)
Study: 32028998
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) study
Study: 32030422
Drug: Sodium zirconium
Normalized name: Sodium zirconium silicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sodium zirconium cyclosilicate (SZC) 10 g three times daily for 24-72 hours followed by 5 g once daily for ≤12 months
Study: 32030422
Drug: Sodium zirconium
Normalized name: Sodium zirconium silicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sodium zirconium cyclosilicate (SZC) 5 g once daily during maintenance phase (MP)
Study: 32030595
Drug: Antipsychotic Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic Medication Management Fidelity Scale
Study: 32031690
Drug: Vasomodulator Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasomodulator Therapy
Study: 32031693
Drug: Lenvatinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib at a dose of 24 mg/day
Study: 32032174
Drug: Anidulafungin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anidulafungin (3 mg/kg on day 1, 1.5 mg/kg daily thereafter) for 5-35 days
Study: 32032309
Drug: Booster vaccine
Normalized name: Moderna COVID-19 (6y+) Bivalent Booster Vaccine PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster vaccine against diphtheria
Study: 32033600
Drug: 200 mcg
Normalized name: CrM 200 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mcg slow-release misoprostol vaginal insert
Study: 32033600
Drug: 25 mcg
Normalized name: D3, 25 mcg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mcg oral misoprostol tablets
Study: 32034017
Drug: Guideline-directed medical
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-directed medical therapy (GDMT) with beta-blockers and RAS inhibitors
Study: 32034017
Drug: Beta-blockers only
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers only
Study: 32034017
Drug: RAS inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAS inhibitors only
Study: 32034416
Drug: Equine-assisted therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equine-assisted therapy (EAT) for PTSD, administered in an eight-session group protocol.
Study: 32034630
Drug: Adavosertib 175
Normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adavosertib 175 mg bid for 2.5 days with carboplatin alone or paclitaxel plus carboplatin
Study: 32034630
Drug: Adavosertib 225
Normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adavosertib 225 mg bid in combination with paclitaxel plus carboplatin
Study: 32034630
Drug: Adavosertib 175
Normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adavosertib 175 mg bid for 2.5 days
Study: 32035752
Drug: Intravenous pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pulse and primed constant infusion of multiple stable tracers of amino acids
Study: 32036486
Drug: Platelet responses
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet responses to other agonists, CD62P platelet surface expression, and PMA levels
Study: 32036499
Drug: PPI augmentation
Normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI augmentation during SBT
Study: 32037403
Drug: Tivozanib (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivozanib (1 mg per os once daily, 21 days on-7 days off)
Study: 32038751
Drug: Lidose-isotretinoin administered
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidose-isotretinoin administered without food
Study: 32040549
Drug: JNJ-64407564 (GPRC5DxCD3
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64407564 (GPRC5DxCD3 bispecific antibody)
Study: 32040562
Drug: Pramipexole (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (0.5 mg/day titrated to a maximum daily dose of 2.5 mg)
Study: 32040562
Drug: Baseline D2/3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline D2/3 receptor availability
Study: 32040573
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum miR-622 expression prior to first-line platinum-based chemotherapy
Study: 32041862
Drug: Lymphodepleting chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphodepleting chemotherapy (intravenous fludarabine and cyclophosphamide)
Study: 32042283
Drug: C1-INH (SC)
Normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1-INH (SC) 40 IU/kg or 60 IU/kg twice weekly for 52 to 140 weeks
Study: 32043771
Drug: De novo
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De novo patients receiving first-line regimens containing chemotherapy (89.7%), trastuzumab (95.7%), and pertuzumab (77.8%)
Study: 32043771
Drug: Recurrent patients
Normalized name: Acacia decurrens extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recurrent patients receiving first-line regimens containing chemotherapy (80.0%), trastuzumab (85.9%), and pertuzumab (68.6%)
Study: 32043777
Drug: Ruxolitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib (5 mg twice daily, with dose increases to 10 mg twice daily permitted after 3 days in the absence of toxicity)
Study: 32043778
Drug: HyperAcute Renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HyperAcute Renal (HAR) immunotherapy
Study: 32043778
Drug: HyperAcute Renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HyperAcute Renal (HAR) immunotherapy (low-dose)
Study: 32043778
Drug: HyperAcute Renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HyperAcute Renal (HAR) immunotherapy (high-dose)
Study: 32044400
Drug: Remestemcel-L (human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remestemcel-L (human mesenchymal stromal cells) administered as 8 biweekly intravenous infusions.
Study: 32045583
Drug: Fixed-dose enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose enoxaparin 40 mg daily
Study: 32045583
Drug: Weight-tiered enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-tiered enoxaparin (30 mg daily for <70 kg, 40 mg daily for 70-89.9 kg, 50 mg daily for ≥90 kg)
Study: 32046348
Drug: CC genotype
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC genotype of the rs699947 variant
Study: 32046725
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation (MBP) + Oral antibiotics (OA)
Study: 32047645
Drug: High-dose cholecalciferol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cholecalciferol supplementation (20,400 IU every other day)
Study: 32047645
Drug: Low-dose cholecalciferol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cholecalciferol supplementation (400 IU every other day)
Study: 32047896
Drug: Late acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late acute GVHD (L-aGVHD)
Study: 32047896
Drug: Active L-aGVHD
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active L-aGVHD before day 114
Study: 32047896
Drug: No cGVHD/L-aGVHD
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cGVHD/L-aGVHD
Study: 32048179
Drug: Oral cannabidiol-rich
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cannabidiol-rich cannabis extracts
Study: 32048179
Drug: Co-administration with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration with zonisamide
Study: 32048179
Drug: Co-administration with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration with levetiracetam
Study: 32048753
Drug: N-of-1 trials
Normalized name: (Alginate)n+1
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-of-1 trials with effective treatment for at least one month
Study: 32048808
Drug: Family-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based treatment (FBT) for childhood obesity, duration: 6 months
Study: 32048808
Drug: Family-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based treatment (FBT) for childhood obesity, sessions 10 to 20
Study: 32048889
Drug: Combined DTPa-IPV/Hib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course and a booster dose
Study: 32049318
Drug: peg-IFN treatment
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peg-IFN treatment
Study: 32050447
Drug: Aerosolised plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolised plus intravenous vancomycin; dosage and duration not specified
Study: 32050447
Drug: Control group;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group; treatment not specified
Study: 32052264
Drug: Mirogabalin 5
Normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mirogabalin 5 mg BID
Study: 32052264
Drug: Mirogabalin 10
Normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mirogabalin 10 mg BID
Study: 32052315
Drug: HPR and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPR and β-amyloid > 51 mg/dl
Study: 32052315
Drug: HPR and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPR and MOTS-c < 167 ng/ml
Study: 32053203
Drug: Analytical Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analytical Treatment Interruption (ATI)
Study: 32053612
Drug: Citicoline 1000
Normalized name: citicoline 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline 1000 mg once daily for 12 months
Study: 32053771
Drug: Celyvir (autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celyvir (autologous MSCs carrying oncolytic adenovirus), administered intravenously, 2 × 10^9 cells weekly for 6 weeks
Study: 32054150
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint blocker (ICB) therapy